Dr. Jonas Schluter, PHD

Leveraging the gut microbiome in lymphoma CAR T-cell therapy

CAR T-cell therapy shows promise for lymphoma, but success rates vary. We propose that deliberate microbiome perturbation could enhance anti-tumor activity during specific therapy moments. With machine-learning analysis of patient data and experiments, we investigate microbiome perturbation strategies that activate and redistribute innate immune cells for better therapy responses.